This can be demonstrated by the CancerSEEK multi-analyte blood test, which combines the detection of a ctDNA mutation (the majority of which are tumor-specific) with presence of traditional biomarkers (Ca125, CEA, Ca19-9) and less widely used blood borne proteins, including hepatocyte growth factor (HGF), osteopontin (OPN), myeloperoxidase (MPO), and tissue inhibitor of metalloproteinases 1 (TIMP-1) to improve sensitivity (129). This evidence concerns the gene HGF and neoplasm.